148 related articles for article (PubMed ID: 27606546)
21. Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
Chen C; Hou X; Wang G; Pan W; Yang X; Zhang Y; Fang H
Eur J Med Chem; 2017 Jun; 133():11-23. PubMed ID: 28371677
[TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of novel annulated thienopyrimidines as phosphodiesterase 5 (PDE5) inhibitors.
El-Sharkawy LY; El-Sakhawy RA; Abdel-Halim M; Lee K; Piazza GA; Ducho C; Hartmann RW; Abadi AH
Arch Pharm (Weinheim); 2018 May; 351(5):e1800018. PubMed ID: 29656464
[TBL] [Abstract][Full Text] [Related]
23. Pharmacophore based virtual screening, molecular docking and biological evaluation to identify novel PDE5 inhibitors with vasodilatory activity.
Mittal A; Paliwal S; Sharma M; Singh A; Sharma S; Yadav D
Bioorg Med Chem Lett; 2014 Jul; 24(14):3137-41. PubMed ID: 24856068
[TBL] [Abstract][Full Text] [Related]
24. Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.
Fiorito J; Saeed F; Zhang H; Staniszewski A; Feng Y; Francis YI; Rao S; Thakkar DM; Deng SX; Landry DW; Arancio O
Eur J Med Chem; 2013 Feb; 60():285-94. PubMed ID: 23313637
[TBL] [Abstract][Full Text] [Related]
25. Identification of novel class I and class IIb histone deacetylase inhibitor for Alzheimer's disease therapeutics.
Gupta R; Ambasta RK; Kumar P
Life Sci; 2020 Sep; 256():117912. PubMed ID: 32504755
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.
De Vreese R; D'hooghe M
Eur J Med Chem; 2017 Jul; 135():174-195. PubMed ID: 28453994
[TBL] [Abstract][Full Text] [Related]
27. Targeting HDACs: a promising therapy for Alzheimer's disease.
Xu K; Dai XL; Huang HC; Jiang ZF
Oxid Med Cell Longev; 2011; 2011():143269. PubMed ID: 21941604
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Class IIa Histone Deacetylases Expression and In Vivo Epigenetic Imaging in a Transgenic Mouse Model of Alzheimer's Disease.
Chen YA; Lu CH; Ke CC; Chiu SJ; Chang CW; Yang BH; Gelovani JG; Liu RS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445342
[TBL] [Abstract][Full Text] [Related]
29. Optimizing metabolic stability of phosphodiesterase 5 inhibitors: Discovery of a potent N-(pyridin-3-ylmethyl)quinoline derivative targeting synaptic plasticity.
Zuccarello E; Zhang H; Acquarone E; Pham D; Staniszewski A; Deng SX; Landry DW; Arancio O; Fiorito J
Bioorg Med Chem Lett; 2023 Aug; 92():129409. PubMed ID: 37453616
[TBL] [Abstract][Full Text] [Related]
30. Inside HDAC with HDAC inhibitors.
Bertrand P
Eur J Med Chem; 2010 Jun; 45(6):2095-116. PubMed ID: 20223566
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and evaluation of N
Pobsuk N; Paracha TU; Chaichamnong N; Salaloy N; Suphakun P; Hannongbua S; Choowongkomon K; Pekthong D; Chootip K; Ingkaninan K; Gleeson MP
Bioorg Med Chem Lett; 2019 Jan; 29(2):267-270. PubMed ID: 30509781
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and in vitro evaluation of new fluorinated quinoline derivatives with high affinity for PDE5: Towards the development of new PET neuroimaging probes.
Liu J; Maisonial-Besset A; Wenzel B; Canitrot D; Baufond A; Chezal JM; Brust P; Moreau E
Eur J Med Chem; 2017 Aug; 136():548-560. PubMed ID: 28544981
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of type 5 phosphodiesterase counteracts β2-adrenergic signalling in beating cardiomyocytes.
Isidori AM; Cornacchione M; Barbagallo F; Di Grazia A; Barrios F; Fassina L; Monaco L; Giannetta E; Gianfrilli D; Garofalo S; Zhang X; Chen X; Xiang YK; Lenzi A; Pellegrini M; Naro F
Cardiovasc Res; 2015 Jun; 106(3):408-20. PubMed ID: 25852085
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
Pabba C; Gregg BT; Kitchen DB; Chen ZJ; Judkins A
Bioorg Med Chem Lett; 2011 Jan; 21(1):324-8. PubMed ID: 21109435
[TBL] [Abstract][Full Text] [Related]
35. Dissecting structure-activity-relationships of crebinostat: Brain penetrant HDAC inhibitors for neuroepigenetic regulation.
Ghosh B; Zhao WN; Reis SA; Patnaik D; Fass DM; Tsai LH; Mazitschek R; Haggarty SJ
Bioorg Med Chem Lett; 2016 Feb; 26(4):1265-1271. PubMed ID: 26804233
[TBL] [Abstract][Full Text] [Related]
36. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
Tashima T; Murata H; Kodama H
Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
[TBL] [Abstract][Full Text] [Related]
37. Benzimidazole and imidazole inhibitors of histone deacetylases: Synthesis and biological activity.
Bressi JC; de Jong R; Wu Y; Jennings AJ; Brown JW; O'Connell S; Tari LW; Skene RJ; Vu P; Navre M; Cao X; Gangloff AR
Bioorg Med Chem Lett; 2010 May; 20(10):3138-41. PubMed ID: 20392637
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and biological evaluation of pyrazolopyrimidinone based potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
Reddy GL; Dar MI; Hudwekar AD; Mahajan P; Nargotra A; Baba AM; Nandi U; Wazir P; Singh G; Vishwakarma RA; Syed SH; Sawant SD
Bioorg Chem; 2019 Aug; 89():103022. PubMed ID: 31181491
[TBL] [Abstract][Full Text] [Related]
39. Utilization of halogen bond in lead optimization: a case study of rational design of potent phosphodiesterase type 5 (PDE5) inhibitors.
Xu Z; Liu Z; Chen T; Chen T; Wang Z; Tian G; Shi J; Wang X; Lu Y; Yan X; Wang G; Jiang H; Chen K; Wang S; Xu Y; Shen J; Zhu W
J Med Chem; 2011 Aug; 54(15):5607-11. PubMed ID: 21714539
[TBL] [Abstract][Full Text] [Related]
40. Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation.
Aboeldahab AMA; Beshr EAM; Shoman ME; Rabea SM; Aly OM
Eur J Med Chem; 2018 Feb; 146():79-92. PubMed ID: 29396364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
